Welcome to our dedicated page for Adaptimmune Therapeutics Plc news (Ticker: ADAP), a resource for investors and traders seeking the latest updates and insights on Adaptimmune Therapeutics Plc stock.
Adaptimmune Therapeutics plc (ADAP) generates a steady flow of news centered on its work in engineered T cell receptor (TCR) cell therapies for solid tumor cancers. Company announcements cover clinical progress, regulatory milestones, commercial activity, strategic transactions and corporate restructuring, providing context for how its business and ADAP stock have evolved over time.
Recent news highlights include the launch and commercial metrics for TECELRA, an engineered T-cell therapy that Adaptimmune describes as the first such therapy approved in the U.S. for a solid tumor cancer, as well as pivotal trial results and regulatory plans for lete-cel in synovial sarcoma and myxoid/round cell liposarcoma. Releases detail Authorized Treatment Center activation, patient aphereses, invoiced doses and manufacturing performance, giving readers insight into how the company has executed on its sarcoma franchise.
Investors following ADAP news will also find coverage of Adaptimmune’s definitive agreement and subsequent transaction with US WorldMeds, under which the company sold the assets and rights related to Tecelra, lete-cel, afami-cel and uza-cel. These stories explain the upfront and potential milestone payments, transfer of employees, and associated transition and license agreements. Additional updates describe the repayment of debt to Hercules Capital and the company’s efforts to maximize value from remaining preclinical assets such as PRAME- and CD70-directed programs.
Other Adaptimmune news items focus on Nasdaq listing compliance notices, the Board’s decision to voluntarily delist the company’s ADSs from The Nasdaq Capital Market and pursue deregistration, and the expectation that trading may move to an over-the-counter market. Executive leadership changes, headcount reductions, cost-saving initiatives and going concern disclosures are also covered. For readers tracking ADAP, this news page brings together financial results, regulatory filings, scientific conference presentations and strategic updates in one place.
Adaptimmune Therapeutics plc (Nasdaq: ADAP) has priced an underwritten public offering of 20.5 million American Depositary Shares (ADSs) at $11.00 each, aiming for a gross size of $225.5 million. The offering will support the advancement of Adaptimmune’s immunotherapy development and general corporate purposes. Underwriters have a 30-day option to purchase an additional 3.075 million ADSs. The offering is expected to close around June 4, 2020, pending customary conditions. Cowen and SVB Leerink are jointly managing the offering.
Adaptimmune Therapeutics (Nasdaq: ADAP) reported significant developments in its latest press release. The company received a $50 million upfront payment from Astellas and completed an offering generating approximately $90 million. Financial guidance confirmed that funds will last into 2H 2021. The EU granted Orphan Drug Designation for ADP-A2M4, enhancing its position alongside existing US designations. Upcoming presentations scheduled for major scientific meetings will showcase data on ADP-A2M4 and other programs. The company's net loss for Q1 2020 was $28.2 million.
Adaptimmune Therapeutics (Nasdaq: ADAP) presented significant advancements in its allogeneic T-cell therapy platform at the ASGCT Annual meeting. The company has successfully engineered T-cells from human induced pluripotent stem cells (hiPSCs) that can target and kill MAGE-A4+ cancer cells in vitro. A milestone was achieved with the editing of T-cell receptor expression into hiPSCs' genome, which is crucial for creating large banks of functional T-cells. These developments mark essential progress toward potential clinical applications of Adaptimmune's proprietary therapies.
Summary not available.